You know that moment in the movie when the villain thinks he's fooled everyone, but the detective shows up with the evidence folder and says: "Have a seat — this is going to be a long conversation"?
Yeah. That's exactly what happened to UniQure — a Dutch biotech that swore it had the silver bullet for Huntington's disease — when a senior FDA official decided to lay it all out on a call with reporters this Thursday.
The Slap
No beating around the bush, no corporate euphemisms — the guy just kept it real:
"What's really going on here? UniQure is the latest company to create a failed therapy for Huntington's patients. They probably recognize, deep down, that their clinical trial failed years ago."
Damn. That's not a bureaucratic press release. That's an uppercut.
The official went on to say that instead of doing the right thing — running a proper clinical study — UniQure is "conducting a distorted and manipulated comparison in the FDA's face."
Translating from bureaucrat-speak to plain English: the company used an external database as a control group instead of running the gold-standard study — randomized, double-blind, placebo-controlled. That study where half the patients get the real drug and half get sugar pills, and nobody knows who's who. The absolute basics of serious science.
UniQure's Excuse
And what was the company's argument for not running the study properly? That it wouldn't be "ethical" to subject patients to a sham brain surgery lasting hours under general anesthesia just to serve as a placebo.
Okay, I get the ethical concern. Genuinely. Brain surgery isn't like getting a wart removed. But the FDA disputed that characterization. And here's the problem: when you want to get approval for a gene therapy that's injected directly into the brain, the burden of proof is on you, not the regulator.
It's the old principle Taleb has hammered a thousand times: extraordinary claims require extraordinary evidence. You want to convince the world that your gene therapy works for one of the most devastating neurodegenerative diseases in existence? Then prove it. With real data. Not with an Excel spreadsheet comparing your patients to some random database.
The Public Fight
This has turned into a soap opera. FDA Commissioner Marty Makary had already taken a jab at UniQure last week in a CNBC interview — without naming the company, but describing the treatment in a way that everyone figured out immediately.
UniQure fired back accusing the FDA of shifting its position — saying the agency had previously agreed that the clinical trial data would be sufficient to pursue approval.
The FDA clapped back: "We never agreed to accept this distorted comparison. The FDA never gives those guarantees. We always say: 'We'll look at the data when it comes in.'"
In other words: UniQure heard what it wanted to hear. Like that investor who asks the analyst "do you think it could go up?" and the guy answers "anything's possible" — and the dude goes out buying on leverage because "the analyst said to buy."
The Market Has Already Rendered Its Verdict
UniQure's stock has already dropped 58% this year. Fifty-eight percent. Oddly enough, on the day of the bombshell statement, the stock jumped over 10%. Go figure. Probably that classic short-squeeze rally mixed with "at least now the uncertainty has decreased" — the twisted market logic we all know and love.
But look: when the regulator itself calls your therapy a "failure" on a call with the press, the signal is crystal clear. This isn't some bank analyst trying to tank the stock. This isn't a short seller putting out a report. This is the referee saying the goal was disallowed.
The Bigger Picture
This is happening at a time when the FDA is under crossfire over a string of rejected drug approval applications. Several companies have accused the agency of walking back previous guidance. There's real tension between the industry and the regulator.
But tension doesn't change facts. And the fact is: if your therapy truly worked, unequivocally, you wouldn't need statistical gymnastics to prove it.
Huntington's disease is a brutal sentence. The families living with it deserve hope — but real hope, based on robust science. Not from a company that wants to skip steps because the right steps are expensive and time-consuming.
The question remains: how many more biotechs are going to try selling promises as if they were results — and how long will investors keep buying that story?
